Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010590 · ClinicalTrials.gov registry record · Phase 4
Anabolic Therapy in Postmenopausal Osteoporosis
A Phase 4 study of Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05010590: Active Phase 4 study of Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.
NCT05010590 is a Phase 4 study of Postmenopausal Osteoporosis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 517-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05010590, a Phase 4 study of Postmenopausal Osteoporosis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
Primary Outcome
Change in total hip bone density between month 0 and month 12
Conditions Studied
Interventions
- DRUG Romosozumab
- DRUG Denosumab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 4 |
What the registry record for NCT05010590 still lists
NCT05010590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 517-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Romosozumab is the first listed.
NCT05010590 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05010590 about?
NCT05010590 is a clinical study titled "Anabolic Therapy in Postmenopausal Osteoporosis". In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
What is the current status of trial NCT05010590?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2022-03-24. Estimated completion is 2027-11-01.
What conditions does trial NCT05010590 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT05010590?
The interventions under investigation include: Romosozumab (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT05010590?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05010590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05010590's enrollment target sits among peer trials
50 15th of 14 the lowest of 14 other Postmenopausal Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
COMPLETED · Phase 4
-
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
COMPLETED · Phase 4
-
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
COMPLETED · Phase 4
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI